Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-18 · accession 0000950170-24-018174 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-21 | 2024-02-18 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +13.2K | 200.6K | +7% | — |
| D | 2024-02-21 | 2024-02-20 | CRSP | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $79.67 | -6,370 | 194.3K | -3% | -$507.5K |
| D | 2024-02-21 | 2024-02-18 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | — | -13.2K | 26.5K | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-02-18 | M | A | 13,250 | — | 200,627 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. |
| 2 | Common | Common Shares | 2024-02-20 | S | D | 6,370 | $79.67 | 194,257 | D | — | — | (F2) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| 3 | Derivative | Restricted Stock Units | 2024-02-18 | M | D | 13,250 | — | 26,500 | D | — · — to — | 13,250 Common Shares | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F3) This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. |